First Time Loading...

Samsung Biologics Co Ltd
KRX:207940

Watchlist Manager
Samsung Biologics Co Ltd Logo
Samsung Biologics Co Ltd
KRX:207940
Watchlist
Price: 736 000 KRW -1.87%
Updated: Jun 10, 2024

Operating Margin
Samsung Biologics Co Ltd

29.2%
Current
31%
Average
2.3%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
29.2%
=
Operating Profit
1.1T
/
Revenue
3.9T

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
KR
Samsung Biologics Co Ltd
KRX:207940
52.4T KRW
29%
US
Thermo Fisher Scientific Inc
NYSE:TMO
221.8B USD
17%
US
Danaher Corp
NYSE:DHR
194.8B USD
22%
CH
Lonza Group AG
SIX:LONN
36.1B CHF
20%
US
IQVIA Holdings Inc
NYSE:IQV
39.9B USD
14%
US
Agilent Technologies Inc
NYSE:A
38.8B USD
20%
US
Mettler-Toledo International Inc
NYSE:MTD
30.7B USD
29%
IE
ICON PLC
NASDAQ:ICLR
26.4B USD
13%
US
West Pharmaceutical Services Inc
NYSE:WST
23B USD
23%
FR
Sartorius Stedim Biotech SA
PAR:DIM
17B EUR
15%
US
Illumina Inc
NASDAQ:ILMN
18.1B USD
-1%
Samsung Biologics Co Ltd
KRX:207940
Country KR
Market Cap 52.4T KRW
Operating Margin
29%
Thermo Fisher Scientific Inc
NYSE:TMO
Country US
Market Cap 221.8B USD
Operating Margin
17%
Danaher Corp
NYSE:DHR
Country US
Market Cap 194.8B USD
Operating Margin
22%
Lonza Group AG
SIX:LONN
Country CH
Market Cap 36.1B CHF
Operating Margin
20%
IQVIA Holdings Inc
NYSE:IQV
Country US
Market Cap 39.9B USD
Operating Margin
14%
Agilent Technologies Inc
NYSE:A
Country US
Market Cap 38.8B USD
Operating Margin
20%
Mettler-Toledo International Inc
NYSE:MTD
Country US
Market Cap 30.7B USD
Operating Margin
29%
ICON PLC
NASDAQ:ICLR
Country IE
Market Cap 26.4B USD
Operating Margin
13%
West Pharmaceutical Services Inc
NYSE:WST
Country US
Market Cap 23B USD
Operating Margin
23%
Sartorius Stedim Biotech SA
PAR:DIM
Country FR
Market Cap 17B EUR
Operating Margin
15%
Illumina Inc
NASDAQ:ILMN
Country US
Market Cap 18.1B USD
Operating Margin
-1%

Profitability Report

View the profitability report to see the full profitability analysis for Samsung Biologics Co Ltd.

Full Profitability Report

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
29.2%
=
Operating Profit
1.1T
/
Revenue
3.9T
What is the Operating Margin of Samsung Biologics Co Ltd?

Based on Samsung Biologics Co Ltd's most recent financial statements, the company has Operating Margin of 29.2%.

ALPHA SPREAD
Join more than 145,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.